Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma

Science Advances(2020)10.1126/sciadv.aaz9798Source: DataRank Database

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma is a research paper published in Science Advances (2020). On theSindex it has a DataRank of 0. It has been cited 54 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access54 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 4.52)OA: goldTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Andrew Z. Wang ORCID,Steven Park ORCID,Kin Man Au ORCID

Live enrichment

PubMed:32270047 PMC:PMC7112753 OpenAlex:https://openalex.org/W3014637308

National Institutes of Health

Grant: U54-CA151652

American Cancer Society

Grant: 126601-MRSG-14-215-01-TBG

National Cancer Institute

Grant: R01CA178748

NCI NIH HHS

Grant: P30 CA016086

NCI NIH HHS

Grant: U54 CA151652

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 1U54CA151652-01

Developmental Projects and Trans-Alliance Activities

National Institutes of Health

Grant: 3P30CA016086-42S2

Cancer Center Support Grant

National Institutes of Health

Grant: 5R01CA178748-03

Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy

FWCI

4.52

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://advances.sciencemag.org/content/advances/6/14/eaaz9798.full.pdf

publisherhttps://advances.sciencemag.org/content/advances/6/14/eaaz9798.full.pdf

publisherhttps://www.science.org/doi/pdf/10.1126/sciadv.aaz9798

journalhttps://doi.org/10.1126/sciadv.aaz9798

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32270047

Fields of Study

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy research0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsDisease Models, AnimalDrug CompoundingHLA-DR AntigensHumansImidazolesLymphoma, Non-HodgkinQuinolinesTissue DistributionImmunophenotypingTreatment OutcomeAntigens, CD20Phosphatidylinositol 3-KinasesXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsNanoparticlesTOR Serine-Threonine Kinases

Keywords

PI3K/AKT/mTOR pathwayLymphomaCancer researchMedicinePharmacologyIn vivoChemistryImmunologyBiologySignal transductionBiochemistryDrug CompoundingLymphoma, Non-HodgkinTOR Serine-Threonine KinasesImidazolesHLA-DR AntigensAntigens, CD20Xenograft Model Antitumor AssaysImmunophenotypingDisease Models, AnimalPhosphatidylinositol 3-KinasesTreatment OutcomeCell Line, TumorQuinolinesAnimalsHumansNanoparticlesTissue DistributionProtein Kinase InhibitorsResearch Articles

Sustainable Development Goals

SDG 3: 3. Good health

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma

FAIR Checklist

Authors (3)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)